Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294529 | 0.88 | GLA (0.59) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL293472 | 0.86 | GLA (0.57) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL7555206 | 0.84 | GLA (0.56) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL7557900 | 0.84 | GLA (0.56) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL294490 | 0.84 | GLA (0.56) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL7557661 | 0.84 | GLA (0.56) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL7551563 | 0.84 | GLA (0.56) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL293102 | 0.82 | L3MBTL1 (0.59) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL9415751 | 0.82 | GLA (0.67) | L3MBTL1TSHRPOLBGLALMNA | |
| SCHEMBL7694058 | 0.80 | GLA (0.65) | L3MBTL1TSHRPOLBGLALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492536-B1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-09 | — | — | EP | claimed |
| US-7456189-B2 | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-25 | — | — | US | claimed |
| EP-1014962-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2007-06-27 | — | — | EP | claimed |
| US-7119084-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-10 | — | — | US | claimed |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | claimed |
| EP-1019045-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2005-06-08 | — | — | EP | claimed |
| US-20050070560-A1 | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-31 | — | — | US | claimed |
| US-20040204367-A1 | Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis | G.D. SEARLE & CO. (US) | 2004-10-14 | — | — | US | claimed |
| EP-1007037-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2004-10-06 | — | — | EP | claimed |
| EP-1007037-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-06-14 | — | — | EP | claimed |
| EP-0999834-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999000128-A9 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 1999-08-05 | — | — | WO | claimed |
| WO-1999000126-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | claimed |
| WO-1999000127-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | claimed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | claimed |
| WO-1999000128-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | claimed |
| EP-0337765-B1 | ACYLSULFONAMIDE DERIVATIVES OF ALPHA-CARBOCYCLYLTOLUIC ACIDS USED AS LEUKOTRIENE ANTAGONISTS | ICI AMERICAS INC. (US) | 1992-10-14 | — | — | EP | claimed |
| US-5095038-A | Antiinflammatory, antiallergens | ICI AMERICAS INC. (US) | 1992-03-10 | — | — | US | claimed |
| EP-0337765-A2 | Acylsulfonamide derivatives of alpha-carbocyclyltoluic acids used as leukotriene antagonists | ICI AMERICAS INC. (US) | 1989-10-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204367-A1 | Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis | ARGLU1, PRR12, PTMS | L3MBTL1 1856/4885TSHR 1453/4885POLB 2549/4885 |
| US-20050070560-A1 | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation | BPHL, BRDT, PKD1 | L3MBTL1 4775/4885TSHR 1766/4885POLB 1532/4885 |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B2, CYP11B1, HPGD | L3MBTL1 4617/4885TSHR 3476/4885POLB 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.